A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

Authors

• William Kelly

Publication/Presentation Date

6-2022

Volume

40

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2022.40.16_suppl.TPS5105

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article